RxDoctor Payments DataLook up a doctor →

Mikell Jarratt, MD

Pulmonary Disease · Gastonia, NCNPI 1497785604

Payments from drug & device makers

$1,729,686in general payments, 2019–2025

Across 1,218 payments — averaging $1420.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$438K
  • Novartis$353K
  • GSK$258K
  • Mallinckrodt Enterprises LLC$123K
  • Merck$104K
  • Astrazeneca AB$81K
  • plus $372K from 54 others
$1,423in research payments, 2019–2025

Across 8 payments — averaging $177.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca126$437,688
Novartis28$353,347
GSK175$258,261
Mallinckrodt Enterprises LLC13$123,439
Merck50$103,957
Astrazeneca AB4$80,539
Shionogi Inc20$74,001
Sanofi US Services Inc.26$70,697
Insmed, Inc.172$54,198
Sanofi50$51,315
Mallinckrodt Hospital Products Inc.23$39,922
Amgen(2 entities)22$22,004
Novo Nordisk AS7$14,850
Boehringer Ingelheim International GmbH4$12,665
Astrazeneca UK Limited1$10,350
Pfizer14$7,178
Chiesi USA, Inc.4$5,030
Viiv Healthcare Company1$1,600
Boehringer Ingelheim58$1,145
Novo Nordisk50$763
Regeneron Healthcare Solutions, Inc.28$702
Lilly USA, LLC37$661
Johnson & Johnson41$580
Mylan Specialty L.p.41$570
Actelion Pharmaceuticals US, Inc.22$518
Bayer29$453
AbbVie21$353
Radius Health, Inc.12$276
Electromed, Inc.14$213
Philips North America LLC7$180
Harmony Biosciences LLC7$165
Grifols USA, LLC8$143
Verona Pharma, Inc.6$132
Avadel CNS Pharmaceuticals, LLC6$131
Pulmonx Corporation4$125
Paratek Pharmaceuticals, Inc.6$90
Shield Therapeutics Inc5$84
Inogen, Inc.5$83
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$83
Sanofi-aventis U.S. LLC4$78
Genentech USA, Inc.6$78
Sunovion Pharmaceuticals Inc.5$71
Inspire Medical Systems, Inc.3$62
Nabriva Therapeutics, PLC3$62
Circassia Inc.4$59
Amarin Pharma, Inc.4$59
Takeda Pharmaceuticals U.S.A., Inc.3$57
Viatris Specialty LLC3$54
Eisai Inc.3$51
Abbott2$47
Masimo Corporation1$46
Biohaven Pharmaceutical Holding Company Ltd.2$42
Resmed Corp1$39
Cequr Corporation1$37
3b Medical, Inc.1$35
CSL Behring1$34
Biohaven Pharmaceuticals, Inc.2$34
Abiomed1$33
Jazz Pharmaceuticals Inc.2$32
Baxter Healthcare1$29

How this compares

$1,729,686 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina →

Medicare billing

Part B allowed, 2024
$127,290
Medicare patients
385
Services billed
1,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Gastonia

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →